Results 201 to 210 of about 38,595 (290)

Fast Quantitative Evaluation of the Amelioration Effect in MASLD During Semaglutide Treatment Using Ultrasound‐Derived Fat Fraction and Fat‐to‐Muscle Ratio

Portal Hypertension &Cirrhosis, Volume 5, Issue 2, Page 117-128, June 2026.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a chronic liver disease. Research into a feasible, rapid, and effective assessment method is crucial for evaluating the therapeutic effects of semaglutide in MASLD. This prospective study utilized ultrasound‐derived fat fraction measurement and fat‐to‐muscle ratio to evaluate hepatic ...
Yunlin Huang, Ruping Yang, Ying Wang, Xiu‐Yun Lu, Li Wei, Rui Cheng, Juan Cheng, Yijie Qiu, Shiwen Wang, Bo Li, Yi Dong   +10 more
wiley   +1 more source

<i>Alea Iacta Est</i>: Casting the Die in Favor of Evidence-Based, Rational GLP-1RA Use. [PDF]

Hosp Pharm
Belančić A.
europepmc   +1 more source

Refining inflammatory profiles linked to cardiometabolic outcomes in people with HIV using recursive feature addition modelling

Clinical and Translational Medicine, Volume 16, Issue 6, June 2026.
Rachel MacCann, Dana Alalwan, Gurvin Saini, Alejandro Abner Garcia Leon, Jesvin Xavier, Matthew Hunter, Fiorina Rigonat, Polina Smolovyk, Maarten F. Schim van der Loeff, Neeltje Kootstra, Padraig McGettrick, Aoife G. Cotter, Alan Winston, Peter Reiss, Caroline Sabin, Patrick W. Mallon, the UPBEAT‐CAD, AIID and COBRA cohorts   +17 more
wiley   +1 more source

Prevalence and Severity of Coronary Artery Calcification Assessed by Low‐Dose Computed Tomography in Individuals With Type 2 Diabetes With and Without Diabetic Foot: A Cross‐Sectional Study

Journal of Diabetes, Volume 18, Issue 6, June 2026.
Diabetic foot is independently associated with the presence and severity of coronary artery calcification in patients with type 2 diabetes. Patients developing diabetic foot or with impaired renal function may warrant enhanced cardiovascular risk assessment and screening for silent coronary artery disease.
Feiyan Shi, Yun Gao, Mingxin Bai, Ruixue Feng, Chunjie Ma, Dawei Chen, Chun Wang, Lihong Chen, Sen He, Donge Yan, Chunchao Xia, Xingwu Ran   +11 more
wiley   +1 more source

GLP-1RA in JBMMSCs promoted osteogenic differentiation via modulating CREB and BRD4 signaling mediated proliferation and stemness. [PDF]

Sci Rep
Liu H, Tian Y, Bao X, Li Y.
europepmc   +1 more source

Urine Proteomic Profiling at Admission Reveals Complement Biomarkers Linked to Alcohol‐Associated Liver Disease

Alcohol, Clinical and Experimental Research, Volume 50, Issue 6, June 2026.
Patients with alcohol‐associated hepatitis (AH) and alcohol‐cirrhosis (AC) show perturbations in complement. Complement activation pathways are perturbed in the urine of patients with AH and AC, and distinguish severe AH from AC. Complement perturbations can help physicians and researchers to understand the liver–kidney crosstalk in severe AH and AC ...
Luan Prado, Ryan Musich, Moyinoluwa Taiwo, Vai Pathak, Daniel M. Rotroff, Annette Bellar, Nicole Welch, Jaividhya Dasarathy, David Streem, for the AlcHepNet, Srinivasan Dasarathy, Laura E. Nagy   +11 more
wiley   +1 more source

Cancer risk with GLP-1RA: what can real-world data really tell us? [PDF]

Lancet Reg Health Eur
Jessen N, Støvring H.
europepmc   +1 more source

Learning Mechanisms in Alcohol Use Disorders

Addiction Biology, Volume 31, Issue 6, June 2026.
Learning mechanisms mediate the initiation, maintenance, and treatment of AUD. ABSTRACT Pavlovian and operant learning mechanisms promote and maintain alcohol intake despite aversive consequences. Here, we review the evidence for drug‐associated modifications of basic learning mechanisms during the initiation and maintenance of alcohol use disorders in
Andreas Heinz, Selin Icoez, Yvonne Treusch, Gaetano di Chiara, Melissa G. Halil   +4 more
wiley   +1 more source

Long-acting management of diabetes and associated complications using an injectable thermosensitive hydrogel incorporating IgG-conjugated GLP-1RA. [PDF]

Theranostics
Wang H, Chen Z, Gu S, Wang Y, Wang Y, Gao C, Shi J, Ding J, Wang Q, Yu L.   +9 more
europepmc   +1 more source

Beyond GLP‐1: The Cardiometabolic Potential of Dual GLP‐1/GIP Receptor Agonists

iNew Medicine, Volume 2, Issue 2, June 2026.
Chao Xue
wiley   +1 more source